James A. Reiffel, MD - Novel Oral Anticoagulants - Figure 27
Summary of Clinical Outcomes
This Figure summarizes the efficacy and safety outcomes of the higher, 150-mg dose of dabigatran versus warfarin in the RE-LY trial.[96] As seen in the in the Forrest plot, other than major GI bleeding everything favors dabigatran over warfarin and superiority in terms of stroke reduction of all types of stroke.
Reiffel JA. Am J Med 2013; 126: 00-00.